Quetiapine Tablet, Extended Release
Product Images NDC 70518-4699

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Quetiapine (NDC 70518-4699). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for Quetiapine Tablet Extended-Release 200 mg oral tablet, containing 30 tablets. Label indicates unit dose capsules are yellow. Manufactured by Macleods Pharma, India, repackaged by RemedyRepack Inc., Indiana, PA. Includes warnings to swallow whole and storage instructions at 20-25°C with excursions allowed to 15-30°C.*

FDA Label Image

Quetiapine-fig-1 (Quetiapine Fig 1)

Chemical structure of quetiapine, shown as a dication complex with two associated anions, representing its salt form. The structure features a dibenzothiazepine core with a substituted piperazine ring and an ethanol side chain.*

FDA Label Image

Quetiapine-fig-2 (Quetiapine Fig 2)

A Kaplan-Meier curve chart depicting the proportion of patients with relapse (%) over time in months. It compares two groups labeled 'PLA' and 'QTF XR', showing relapse progression with 'QTF XR' group having a lower relapse proportion over the 7-month period than the 'PLA' group.*

FDA Label Image

Quetiapine-fig-3 (Quetiapine Fig 3)

A line graph depicting the proportion of patients with relapse (%) over time in weeks. It compares two groups labeled as QTP+LIVAL and PLA+LIVAL, showing the difference in relapse rates between them throughout the study period.*

FDA Label Image

Quetiapine-fig-4 (Quetiapine Fig 4)

A line graph showing the proportion of patients with relapse over time (in weeks) for two treatment groups: QTP + LIVAL and PLA + LIVAL. The y-axis represents the percentage of patients with relapse, and the x-axis represents time up to 100 weeks. The QTP + LIVAL group shows a higher cumulative relapse proportion compared to the PLA + LIVAL group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.